Source: European Medicines Agency (EU) Revision Year: 2024 Publisher: Roche Registration GmbH, Emil-Barell-Strasse 1, 79639 Grenzach-Wyhlen, Germany
Vabysmo 120 mg/mL solution for injection.
| Pharmaceutical Form |
|---|
|
Solution for injection. Clear to opalescent, colourless to brownish-yellow solution, with a pH of 5.5 and an osmolality of 270-370 mOsm/kg. |
Faricimab is a humanised antibody produced in mammalian Chinese Hamster Ovary (CHO) cell culture by recombinant DNA technology.
One mL of solution contains 120 mg of faricimab.
Each vial contains 28.8 mg faricimab in 0.24 mL solution. This provides a usable amount to deliver a single dose of 0.05 mL solution containing 6 mg of faricimab.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Faricimab |
Faricimab is a humanised bispecific immunoglobulin G1 (IgG1) antibody that acts through inhibition of two distinct pathways by neutralisation of both angiopoietin-2 (Ang-2) and vascular endothelial growth factor A (VEGF-A). By dual inhibition of Ang-2 and VEGF-A, faricimab reduces vascular permeability and inflammation, inhibits pathological angiogenesis and restores vascular stability. |
| List of Excipients |
|---|
|
L-histidine |
0.24 mL sterile, solution in a glass vial with a coated rubber stopper sealed with an aluminum cap with a yellow plastic flip-off disk.
Pack size of 1 vial and 1 blunt transfer filter needle (18-gauge x 1½ inch, 1.2 mm x 40 mm, 5 µm).
Roche Registration GmbH, Emil-Barell-Strasse 1, 79639 Grenzach-Wyhlen, Germany
EU/1/22/1683/001
Date of first authorisation: 15 September 2022
| Drug | Countries | |
|---|---|---|
| VABYSMO | Austria, Canada, Ecuador, France, Croatia, Ireland, Israel, Italy, Japan, Lithuania, Romania, United Kingdom, United States |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
